All News

DLE discoid lupus

ACR Promotes CME on Lupus Clinical Trials Racial Disparities

ACR

The American College of Rheumatology (ACR) has released Continuing Medical Education (CME) for dermatologists and nephrologists to help them learn more about clinical trials for lupus patients in their respective treatment areas and the importance of getting more of their African American/Black p

Read Article
RheumNow Podcast square

Infections & Lupus (10.28.2022)

Jack Cush, MD

Dr. Jack Cush discusses the news and journal reports from the past week on RheumNow. This week more lupus nephritis, more drug induced lupus and more lupus infections that may kill. 

Read Article
bacteria,infection,color

Infection: a Leading Cause of Death in Lupus

Jack Cush, MD

 Analysis of a national database of hospital discharges from Spain shows that infections accounted for 25% of lupus deaths, making infection the most common cause of death in SLE.

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

Increasing Risk of Lupus Nephritis

Jack Cush, MD

Population based study from Minnesota shows that the incidence of lupus nephritis (LN) in the US has increased in the last four decades and that LN patients have poorer outcomes with high rates of ESRD and mortality rates six times that of the general population.

Read Article
RheumNow Podcast square

ACR Award Winners (10.21.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlighted discussion of implantable stimulators, urine proteomics and gut-immune responses to Prevotella in RA.

Read Article
Prgnancy,outcome

Pregnancy Outcomes with Belimumab

Jack Cush, MD

Pregnancy in systemic lupus erythematosus (SLE) is fraught with problems of adverse pregnancy outcomes, more pregnancy loss and birth defects. Now a study of SLE pregnancies exposed to belimumab (BEL) shows and expected rate of pregnancy loss but a variable rate of birth defects.

Read Article
Infection: a Leading Cause of Death in Lupus Analysis of a national database of hospital discharges from Spain shows that infections accounted for 25% of lupus deaths, making infection the most common cause of death in SLE. https://t.co/uTQd3afwxR https://t.co/okBHWel62d

Links:

Dr. John Cush RheumNow ( View Tweet)
Increasing Risk of Lupus Nephritis A population based study shows that LN in the US has increased in the last four decades and that LN patients have poorer outcomes with high rates of ESRD and mortality rates 6x that of the general population. https://t.co/aBSUP9ExTh https://t.co/RfgSH0wmOu

Links:

Dr. John Cush RheumNow ( View Tweet)
Predictors of serious infection (SIE) in SLE? A prior SIE conferred the highest risk of subsequent SIE. Study of 346 SLE pts shows SIE rate of 3.8/100 Pt-Yrs. Other risk factors: Damage accrual, comorbidity, Dz activity, CTX use https://t.co/hvAtpTUPml https://t.co/QkJp7ssOUU

Links:

Dr. John Cush RheumNow ( View Tweet)
Celebrating my 10,000 followers on TikTok. @Rheum101 is where I make videos teaching rheumatology to the general public in 3 min bites. Topics include #SLE #Steroids #RA #ANA #RheumLabs #DMARDS #biologics #JAKi #osteoporosis #PsA and more #RheumEducation #NotMedicalAdvice https://t.co/WEXspp5v28
TheDaoIndex KDAO2011 ( View Tweet)
Will we see you there? #ACR2022 What are you most looking forward to on the agenda? https://t.co/KQGHJtwboe
Dr. John Cush RheumNow ( View Tweet)
1915 Rheumatic (RMD)pts w/ COVID (42% RA. 15% SLE, 1/2 comorbidities); Outcomes: 28% hospitalized, 8% to ICU & 4% died from COVID-19. Poor COVID-19 outcomes seen w/ age, male, Hi Dz activity, steroids & RTX, & 1+ comorbidity https://t.co/ztBiJc9nxV https://t.co/RVOKyjseFJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Pregnancy Outcomes with Belimumab A study of SLE pregnancies exposed to belimumab (BEL) shows and expected rate of pregnancy loss but a variable rate of birth defects. https://t.co/kybCgu3Rlp https://t.co/ckshcgDZbD

Links:

Dr. John Cush RheumNow ( View Tweet)
Analysis of WHO Safety Vigibase found 625 cases of drug-induced SLE - mostly female (78%), 59 yrs old, w/ half suspecting only PPI. Most common was Omeprazole (30%). Another 800K French database ID 39 pts w/ PPI CLE, half SCLE, 5% DLE https://t.co/vfAArCfWW1 https://t.co/3xQc5NZhvQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine Dosing and SLE Flares A cohort study examining HCQ dosing in patients with SLE suggests that HCQ doses of 5 mg/kg per day or less, was associated with a higher risk of lupus flares, including moderate or severe lupus flares. https://t.co/VCn4hOs1PY https://t.co/bbVeVlD1u0

Links:

Dr. John Cush RheumNow ( View Tweet)
Spondyloenchondrodysplasia - Very rare genetic skeletal dysplasia w/ short stature, platyspondyly, short broad ilia and enchondromas in long bones or pelvis. Varied phenotype w/ CNS (spasticity, retardation) & autoimmune (ITP, SLE, AIHA, thyroiditis) https://t.co/4DHqohjb2Z https://t.co/Bafh1v0MOA

Links:

Dr. John Cush RheumNow ( View Tweet)
Follow us for real time coverage #ACR2022 https://t.co/5CBdiKWdKM
Dr. John Cush RheumNow ( View Tweet)
Pregnancy Outcomes with Belimumab A study of SLE pregnancies exposed to belimumab (BEL) shows and expected rate of pregnancy loss but a variable rate of birth defects. https://t.co/cXm58iSmVc https://t.co/Hdg6Qg1uHE

Links:

Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine Dosing and SLE Flares A cohort study examining HCQ dosing in patients with SLE suggests that HCQ doses of 5 mg/kg per day or less, was associated with a higher risk of lupus flares, including moderate or severe lupus flares. https://t.co/UeIZ70zRnt https://t.co/tGrBSydvKB

Links:

Dr. John Cush RheumNow ( View Tweet)
Urine proteomics on 54 SLE pts in the Belimumab–Lupus Nephritis trial, compared responders (n 31) v non-responders (n 22), on BEL or SOC. Reduction in urinary CD163 was strongly associated with complete renal response @wk52 & CD23 @wk24 https://t.co/PrXaJq6h0E https://t.co/IWREF9VmZ8

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×